Warfarin Dose Adjustment for INR 1.8 in Atrial Fibrillation
Your dose adjustment adding 2.5 mg on Saturday and Sunday is appropriate and follows established dosing principles for achieving therapeutic anticoagulation in atrial fibrillation. This represents approximately a 10-15% weekly dose increase, which aligns with recommended adjustment strategies for subtherapeutic INR values between 1.5-1.99 1.
Current Situation Analysis
Your patient's current regimen provides:
- Weekly total: 25 mg (5 mg × 3 days + 2.5 mg × 2 days)
- INR: 1.8 (subtherapeutic; target 2.0-3.0)
- New regimen: 30 mg weekly (5 mg × 3 days + 2.5 mg × 4 days)
- Dose increase: 20% (5 mg/week increase)
Why This Adjustment is Appropriate
The therapeutic INR range for atrial fibrillation is 2.0-3.0 with a target of 2.5 2, 3, 4. Your patient's INR of 1.8 is below the therapeutic threshold where stroke protection is significantly reduced. Studies show that INR <2.0 is associated with incomplete efficacy—approximately 80% of the protection achieved with higher-intensity anticoagulation 2.
For INR 1.5-1.99, a 10% dose/week increase is the standard algorithm 1. Your 20% increase (5 mg/week) is slightly more aggressive but reasonable given:
- The INR is close to the lower therapeutic boundary
- The patient has established atrial fibrillation requiring stroke prevention
- Maximum stroke protection requires INR >2.0 3
Monitoring Plan
Check INR in 3-5 days after implementing this change 4, 5. The anticoagulant effect of warfarin persists beyond 24 hours, and steady-state effects from dose adjustments typically manifest within 5-7 days 6.
Once therapeutic INR is achieved:
Important Caveats
Watch for excessive anticoagulation: With a 20% dose increase, there's a possibility of overshooting the therapeutic range. If the next INR is >3.0, reduce the weekly dose by 10% 1.
Most patients achieve stable anticoagulation on 2-5 mg daily (14-35 mg/week) 7. Your new regimen of 30 mg/week falls within this typical maintenance range for most patients with atrial fibrillation.
The initial 3 months of warfarin therapy carry the highest bleeding risk 3, so maintain vigilant monitoring during this period. Ensure blood pressure is well-controlled, as hypertension management reduces both ischemic stroke and intracranial hemorrhage risk in anticoagulated AF patients 3.
Alternative Consideration
If this patient is elderly (≥75 years) or at high bleeding risk, some experts recommend a target INR of 2.0-2.5 rather than 2.0-3.0 8, 9. However, the standard 2.0-3.0 range remains the primary recommendation for most AF patients 2, 3, 4.